Stockpiling active pharmaceutical ingredients for critical drugs is prudent. However, domestic production of prioritized auxiliary chemicals must be part of strategy.
President Donald Trump’s playbook is to threaten outrageously high industry-specific tariffs in the hope of pressuring drugmakers to come running back to this country.
The agreement includes a 15% tariff on branded pharmaceutical products imported from the European Union to the United States, elevating costs across the pharma value chain.
With the looming threat of Trump’s tariffs on pharmaceuticals, major drugmakers continue to invest billions of dollars in domestic manufacturing in the United States.
This week’s announcement about a new multibillion-dollar investment in PCI Pharma Services is good news for contract development and manufacturing organizations.
Drug manufacturers have been left in a climate of anxious anticipation and a heightened state of uncertainty as the pharma industry waits to see if the president is bluffing.
While the process has been a buzzword for years, offering an alternative to traditional batch manufacturing, industry uptake has been slow. However, the tide may be turning.
The Tar Heel State’s decades-long focus on economic development in life sciences and pharma manufacturing is bearing fruit, as it looks to rival the Bay Area and Boston.
More than 300 comments have been posted in response to a Department of Commerce investigation into the importation of certain pharmaceuticals and pharma ingredients.
PhRMA warned that President Trump’s executive order on most favored nation would jeopardize hundreds of billions of dollars in planned U.S. investments by its members.
The three Big Pharma companies on their earnings calls this week tried to reassure investors that they have the global footprints to mitigate the effects of tariffs.
President Trump has threatened to impose tariffs on pharmaceuticals, as a Department of Commerce probe on drug imports gets underway. But analysts and stakeholders are skeptical...
Despite Trump pushing drugmakers to bring manufacturing back to the U.S., it remains unclear whether companies — other than Eli Lilly, J&J, and Novartis — will respond.
